Regeneron: A Buy On Dupixent And Pipeline [Seeking Alpha]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Seeking Alpha
Summary Regeneron ( REGN ) is priced nicely for buyers, given its profit growth and clinical pipeline of potential new drugs. Regeneron is a large cap ($38.8 billion) biotechnology pharmaceutical company. It is well below its 52-week high of $505.49, which I see as a good longer-term goal. Returning to $505 would result in a 38% return over the current stock price. REGN data by YCharts The value in the company is in its aging Eylea franchise, its new Dupixent franchise, in its later stage clinical pipeline, and in its proven ability to take drugs from preclinical studies to commercial success. Q2 Results First, a recap of Q2 results will place the financials in perspective. Revenue was $1.61 billion, up 7% sequentially from $1.51 billion and up 9% from $1.47 billion in the year-earlier quarter. GAAP net income was $551 million, up 15% sequentially from $478 million and up 42% from $388 million year earlier. GAAP diluted earnings per share (EPS) was $4
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Biogen: Don't expect any big acquisitions this year [Yahoo! Finance]Yahoo! Finance
- Allergy & Asthma Network Announces Trusted Messengers Health Equity Community Outreach Plans for 2024 [Yahoo! Finance]Yahoo! Finance
- ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update [Yahoo! Finance]Yahoo! Finance
- Gardner Syndrome Treatment Market Report 2024: Analysis and Forecast Through 2018-2033 Featuring Biochem Pharmaceuticals Industries, Zydus Lifesciences, Vernalis (R&D), Sun Pharmaceutical Industries, and Sanofi [Yahoo! Finance]Yahoo! Finance
- Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study [Yahoo! Finance]Yahoo! Finance
SNY
Analyst Actions
- 2/12/24 - TheStreet
SNY
Sec Filings
- 4/4/24 - Form F-3ASR
- 4/4/24 - Form S-8
- 3/20/24 - Form 6-K
- SNY's page on the SEC website